Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

MYLAN NV

(MYL)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2019 04/18/2019 04/22/2019 04/23/2019 04/24/2019 Date
26.73(c) 26.85(c) 26.72(c) 26.6(c) 26.44(c) Last
4 293 006 3 806 669 2 694 766 5 565 097 3 212 929 Volume
-1.26% +0.45% -0.48% -0.45% -0.60% Change
More quotes
Financials (USD)
Sales 2019 11 973 M
EBIT 2019 3 262 M
Net income 2019 1 417 M
Debt 2019 11 548 M
Yield 2019 -
Sales 2020 12 403 M
EBIT 2020 3 418 M
Net income 2020 1 455 M
Debt 2020 9 570 M
Yield 2020 -
P/E ratio 2019 12,79
P/E ratio 2020 12,21
EV / Sales2019 2,11x
EV / Sales2020 1,88x
Capitalization 13 724 M
More Financials
Company
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North... 
Sector
Pharmaceuticals
Calendar
05/08Earnings Release
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
04/18MYLAN : TB Alliance and Mylan Announce Global Collaboration to Commercialize Inv..
PR
04/15U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents
RE
04/03STRIVING TO CREATE BETTER HEALTH FOR : Mylan's Global Social Responsibility 2018..
PR
03/27MYLAN : Emotional Homecoming the First of Many in Puerto Rico with Mylan Charita..
PU
03/18MYLAN : Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovori..
PU
03/07MYLAN : SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Part..
PR
03/01PFIZER : Under U.S. Civil Investigation Over EpiPen Issues
DJ
02/28MYLAN : Pfizer unit Meridian under civil investigation by U.S. Attorney
RE
02/28MYLAN : to Present at Raymond James 40th Annual Institutional Investors Conferen..
PR
02/27MARKET SNAPSHOT: Stocks Close Mostly Lower As Investors Focus On Lighthizer, ..
DJ
More news
Analyst Recommendations on MYLAN NV
More recommendations
Sector news : Pharmaceuticals - NEC
03:01aBAYER : gets Monsanto profit boost but legal burden mounts
RE
02:01aBAYER : 1Q 2019 Profit Fell on Restructuring, Acquisition Costs
DJ
04/24BIOGEN : dips as strategy post Alzheimer's setback fails to impress
RE
04/24BIOGEN : dips as strategy post Alzheimer's setback fails to impress
RE
04/24GLOBAL MARKETS LIVE : Samsung, Wirecard, Boeing, Nissan…
More sector news : Pharmaceuticals - NEC
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 35,9 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Haribabu Bodepudi Chief Operating Officer
Kenneth Scott Parks Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV-3.50%13 724
JOHNSON & JOHNSON8.41%372 522
ROCHE HOLDING LTD.10.11%227 132
PFIZER-9.69%218 852
NOVARTIS4.88%195 750
MERCK AND COMPANY-2.37%192 697